Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274219 | 0.84 | GSK3B (0.49) | GSK3BCYP2D6MAPTSMN1; SMN2POLB | |
| SCHEMBL15673507 | 0.81 | GSK3B (0.39) | GSK3BCYP2D6 | |
| SCHEMBL3273801 | 0.80 | GSK3B (0.47) | GSK3BKAT2BL3MBTL1MAPTLMNA | |
| SCHEMBL3280949 | 0.80 | GSK3B (0.45) | GSK3BCYP2D6POLB | |
| SCHEMBL3278253 | 0.80 | ATM (0.45) | GSK3BCYP2D6POLB | |
| SCHEMBL15673522 | 0.79 | GSK3B (0.45) | GSK3BCYP2D6 | |
| SCHEMBL15673525 | 0.78 | GSK3B (0.39) | GSK3BCYP2D6 | |
| SCHEMBL3274906 | 0.76 | GSK3B (0.42) | GSK3BCYP2D6MAPT | |
| SCHEMBL3275205 | 0.76 | GSK3B (0.41) | GSK3BCYP2D6MAPTSMN1; SMN2 | |
| SCHEMBL3273306 | 0.75 | GSK3B (0.50) | GSK3BCYP2D6SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | claimed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-1992625-A1 | Arylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-2160387-B1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2160388-B1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-8598187-B2 | Arylamide pyrimidone compounds | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| US-8592437-B2 | Heteroarylamide pyrimidone compounds | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2160388-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| EP-2148866-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008155669-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155670-A2 | ARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155668-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992624-A1 | Heteroarylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992625-A1 | Arylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087461-A1 | ARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, HPRT1, XDH | GSK3B 3294/4885CYP2D6 78/4885KAT2B 2774/4885 |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, DPYD, HPRT1 | GSK3B 2561/4885CYP2D6 101/4885KAT2B 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.